VH
Venrock Healthcare Capital Partners
Palo Alto, California, United StatesFounded 2009
Venrock Healthcare Capital Partners focuses on long-term investment opportunities in small capitalization public companies and late-stage private companies within the healthcare and life sciences industry, with a particular emphasis on biopharmaceuticals. They also target early-stage companies in healthcare and technology, seeking disruptive ideas in areas like digital health and biotech, often leading seed and Series A funding rounds.
92% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 4 prior). Average disclosed round size is $173.3M (across 12 rounds with reported amounts).
Portfolio
12
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Tubulis | Series C | $308M | Oct 2025 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Surrozen, Inc. | Series D | $175M | Mar 2025 |
 Adcendo ApS | Series B | $135M | Nov 2024 |
 Lycia Therapeutics, Inc. | Series C | $106.6M | May 2024 |
 Averto Medical Inc | Series A | $30.5M | May 2024 |
 Carmot Therapeutics | Series E | $150M | May 2023 |
 Apogee Therapeutics | Series B | $149M | Dec 2022 |
 Athira Pharma, Inc. | Series B | $85M | Jun 2020 |
 Jade Biosciences | Unknown | $95M | — |
| OOruka Therapeutics | Growth | $275M | — |
 Candid Therapeutics | Growth | $370M | — |
Top Co-Investors
Deep Track Capital6 shared
RTW Investments5 shared
Frazier Life Sciences4 shared
Franklin Templeton4 shared
Braidwell LP4 shared
RA Capital Management4 shared
Fairmount4 shared
Perceptive Advisors3 shared
Logos Capital3 shared
Janus Henderson Investors3 shared
Wellington Management3 shared
LifeSci Venture Partners2 shared
Surveyor Capital2 shared
Avidity Partners2 shared
The Column Group2 shared
Access Biotechnology2 shared
Commodore Capital2 shared
Redmile Group2 shared
OrbiMed2 shared
Versant Ventures1 shared
Last updated: 16 April 2026